Differences in Capacity of High‐Density Lipoprotein Cholesterol Efflux Between Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis

Quevedo-Abeledo, Juan Carlos; Sánchez-Pérez, Hiurma; Tejera-Segura, Beatriz; Armas-Rillo, Laura de; Armas-González, Estefanía; Machado, José David; Dı́az-González, Federico; Ferraz-Amaro, Iván

doi:10.1002/acr.24407

Cited by 18 publications

(13 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…HDL CEC impairment has been reported in various rheumatologic autoimmune diseases, such as RA and systemic lupus erythematosus (SLE) [ 190 , 191 , 192 , 193 , 194 ]. In SLE, HDL CEC was inversely related to subclinical carotid atherosclerosis [ 195 ].…”

Section: Hdl Cec In Specific Conditionsmentioning

confidence: 99%

High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives

Adorni

Ronda

Bernini

et al. 2021

Cells

View full text Add to dashboard Cite

Over the years, the relationship between high-density lipoprotein (HDL) and atherosclerosis, initially highlighted by the Framingham study, has been revealed to be extremely complex, due to the multiple HDL functions involved in atheroprotection. Among them, HDL cholesterol efflux capacity (CEC), the ability of HDL to promote cell cholesterol efflux from cells, has emerged as a better predictor of cardiovascular (CV) risk compared to merely plasma HDL-cholesterol (HDL-C) levels. HDL CEC is impaired in many genetic and pathological conditions associated to high CV risk such as dyslipidemia, chronic kidney disease, diabetes, inflammatory and autoimmune diseases, endocrine disorders, etc. The present review describes the current knowledge on HDL CEC modifications in these conditions, focusing on the most recent human studies and on genetic and pathophysiologic aspects. In addition, the most relevant strategies possibly modulating HDL CEC, including lifestyle modifications, as well as nutraceutical and pharmacological interventions, will be discussed. The objective of this review is to help understanding whether, from the current evidence, HDL CEC may be considered as a valid biomarker of CV risk and a potential pharmacological target for novel therapeutic approaches.

show abstract

Section: Hdl Cec In Specific Conditionsmentioning

confidence: 99%

High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives

Adorni

Ronda

Bernini

et al. 2021

Cells

View full text Add to dashboard Cite

show abstract

“…Decreased CEC has been linked to cardiovascular events in the general population [64,65]. A 2020 study that compared CEC in two autoimmune rheumatic diseases, SLE and rheumatoid arthritis found CEC to be more impaired in SLE [66]. Another cross-sectional study that included 195 SLE patients and 223 controls also found CEC to be compromised in SLE (P = 0.004).…”

Section: Sle Plasma Induces Changes In Cholesterol Handlingmentioning

confidence: 99%

Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention

et al. 2021

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) carries a significant risk of cardiovascular disease (CVD). The prevalence of premature CVD is especially noteworthy because it occurs in premenopausal women with SLE who would otherwise have very low rates of CVD. While traditional risk factors likely play a role in development of CVD in the setting of SLE, they do not fully explain the excess risk. The pathogenesis of CVD in SLE is not fully understood, but the inflammatory nature of SLE is believed to be a key factor in accelerating atherosclerosis. Systemic inflammation may lead to an abnormal lipid profile with elevated triglycerides, total cholesterol, and low-density lipoprotein cholesterol and dysfunctional high-density lipoprotein cholesterol. Additionally, the inflammatory milieu of SLE plasma promotes endothelial dysfunction and vascular injury, early steps in the progression of atherosclerotic CVD. Despite the overall headway that has been achieved in treating lupus, innovative therapeutics specifically targeting the progression of atherosclerosis within the lupus population are currently lacking. However, there have been advancements in the development of promising modalities for diagnosis of subclinical atherosclerosis and detection of high CVD risk patients. Due to the significant impact of CVD on morbidity and mortality, research addressing prevention and treatment of CVD in SLE needs to be prioritized. This review explores the intricate interplay of SLE-specific properties that contribute to atherosclerosis and CVD within this population, as well as screening methods and possible therapies.

show abstract

“…Although SLE was under control in most patients, CEC in patients was lower compared to controls. In a recent study by our group [26], CEC was impaired in SLE patients independently of other in ammation-related lipid pro le modi cations that occurred during the disease. Moreover, CEC was associated with carotid plaques in SLE patients.…”

Section: Discussionmentioning

confidence: 80%

HDL-Cholesterol Efflux Capacity and Lipid Profile in Patients with Systemic Sclerosis.

Ferraz‐Amaro

Delgado-Frías

Hernández-Hernández

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Objective. It is well established that patients with systemic sclerosis (SSc) have a disrupted lipid profile and an increased cardiovascular risk. Cholesterol efflux capacity (CEC), the ability of high-density lipoprotein (HDL)-cholesterol to accept cholesterol from macrophages has been linked to cardiovascular events. The aim of this study was to establish whether CEC and lipid profile were impaired in SSc patients respect to controls and whether these changes were associated with disease-related data. Methods. Cross-sectional study encompassed 188 individuals: 73 SSc patients and 115 controls. CEC, using an in vitro assay, and lipoprotein serum concentrations were assessed in patients and controls. A multivariable analysis was performed to study the differences in CEC between patients and controls, and if SSc-related data could explain such differences. Results. The multivariate analysis adjusted for demographic characteristics, cardiovascular risk factors and lipid-related molecules showed that total cholesterol (beta coefficient: -22 [95%CI -37- -7], p=0.004), triglycerides (beta coefficient: 24 [95%CI 2-47], p=0.033), lipoprotein A (beta coefficient: 22 [95%CI 2-43], p=0.033) and CEC (beta coefficient: -6 [95%CI -10- -2]%,p=0.002) were significantly differences between patients and controls. Skin thickness, as assessed by modified Rodnan skin score, was independently associated with a lower CEC (beta coefficient: -0.21 [95%CI -0.37- -0.05]%, p=0.011) after multivariable adjustment. Conclusion. SSc patients show an abnormal lipid profile with respect to controls including CEC. Skin thickness is independent and inversely associated with CEC in SSc patients.

show abstract

Differences in Capacity of High‐Density Lipoprotein Cholesterol Efflux Between Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis

Cited by 18 publications

References 17 publications

High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives

High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives

Understanding Accelerated Atherosclerosis in Systemic Lupus Erythematosus: Toward Better Treatment and Prevention

HDL-Cholesterol Efflux Capacity and Lipid Profile in Patients with Systemic Sclerosis.

Contact Info

Product

Resources

About